SLQT · SelectQuote, Inc.

SelectQuote delivered Q3 FY2026 results with consolidated revenue growth of 6% to $430.9 million, fueled by 8% Senior segment revenue increase to $182.9 million and 5% Healthcare Services growth to $199.4 million, despite market shifts in Medicare Advantage and prescription drugs. Net income rose to $40.2 million from $26.0 million YoY, while Adjusted EBITDA expanded 18% to $44.6 million. Senior shone with 28% Adjusted EBITDA growth to $58.6 million (32% margin), aided by a $14 million positive change in commissions receivable estimate, solid agent productivity, and improved retention. Approved Medicare Advantage policies reached 175,557, up 4% YoY. Healthcare Services sustained momentum with SelectRx membership at 116,616 (up 11% YoY) and prescriptions per day at 33,209, though Adjusted EBITDA dipped to $5.3 million amid Inflation Reduction Act impacts offset by higher PBM rates. Life revenue grew 4% to $47.9 million with stable profitability. Combined Senior and Healthcare per-unit economics hit a record revenue/CAC multiple of 6.7x (vs 5.8x prior), signaling marketing efficiency and healthcare model value. CEO Tim Danker highlighted consistent profit, cash flow, and $1 billion receivables balance (up ~$50M YoY), positioning for expanded cash flow via SelectRx maturation and capital structure improvements. FY2026 guidance remains unchanged at $1.61-1.71 billion revenue and $90-100 million Adjusted EBITDA, underscoring execution confidence.